Navigation Links
Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Date:10/26/2009

ted in Maisons-Alfort, France, just outside of Paris. Key affiliates are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL® (armodafinil) Tablets [C-IV], TREANDA® (bendamustine hydrochloride) for Injection, AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), FENTORA® (fentanyl buccal tablet) [C-II], TRISENOX® (arsenic trioxide) injection, GABITRIL® (tiagabine hydrochloride), PROVIGIL® (modafinil) Tablets [C-IV], and ACTIQ® (oral transmucosal fentanyl citrate) (C-II). The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

About BioAssets Development Corporation

BioAssets Development Corporation is a private company pioneering novel spine indications for emerging and marketed biologic drugs. The Company's lead initiative focuses on the development of a TNF inhibitor therapy to treat the underlying cause of pain in sciatica. For more information, visit www.biodevco.com.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding whether Cephalon ultimately will acquire BDC, anticipated scientific progress on its research programs, development of potential pharmaceutical products such as an anti-TNF reactor agent, the relative value to Ceph
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... for the third quarter ended September 30, 2014 on ... financial markets. Howard Robin , president and chief ... the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 ... release and a live audio-only Webcast of the conference ...
(Date:10/30/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: ... today announced financial results for the third quarter ... corporate, commercial, regulatory and clinical development updates from ... pleased with the continued momentum and strong performance ... this quarter, especially the XIAFLEX franchise, which more ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... , , MEMPHIS, Tenn. , Jan. 20 ... SN) Orthopaedics business is making available this week more than $2 ... in the treatment of survivors of last week,s earthquake in Haiti ... range of orthopedic surgical resources used to treat bone fractures. , ...
... Fla. , Jan. 20 Roper Industries, ... for the fourth quarter of 2009, ended December 31, 2009 , ... 2010 .  A conference call to discuss these results has been scheduled ... .  The call can be accessed via webcast or by dialing +1 ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Begins Distribution to Haiti of Trauma Implants and Instruments 2Smith & Nephew Orthopaedics Begins Distribution to Haiti of Trauma Implants and Instruments 3
(Date:10/30/2014)... Seattle, WA (PRWEB) October 30, 2014 Sound ... their decision infographic that will assist people any time they ... people discover the right answer by leading them through a ... a resolution to their initial query. , There are many ... or not to use an answering service . This ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Scientists who ... the laboratory say their breakthrough could provide a new ... of stomach diseases. The team used human pluripotent ... cell in the body -- to grow the functional ... bacteria, a major cause of ulcers and stomach ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, ... bad for your health, a new study reports. Previous ... strengthen bones and prevent osteoporosis. These benefits to bone health ... of a healthy diet. But this new study found ... or women from bone fractures, and was linked to an ...
(Date:10/30/2014)... News) -- Eating a low-carb, high-fat diet could help ... new research. A review of five studies ... focuses on foods like bacon, eggs, heavy cream, butter, ... adults whose condition doesn,t improve with medication. "We ... with epilepsy whose seizures are not stopped by medications," ...
(Date:10/30/2014)... (HealthDay News) -- A new vaccine that could help ... approved by the U.S. Food and Drug Administration on ... the ages of 10 and 25 from invasive meningococcal ... bacteria. The bacteria can infect the bloodstream (sepsis) ... brain. It is a leading cause of bacterial meningitis, ...
Breaking Medicine News(10 mins):Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... (HealthDay News) -- Workers with chronic low back pain can ... approach to care instead of traditional medical care, a new ... burden in developed countries, with 93 percent of the losses ... reason, researchers in the Netherlands tested a new approach among ...
... presented today at the annual meeting of the Radiological Society ... in the body of a human drug courier, known as ... from South America is making its way to Europe through ... of Berne and Institute of Forensic Medicine of Berne in ...
... and bottles of over-the-counter (OTC) medicines for children in the ... and follow, according to a study in the December 1 ... an unacceptable amount of inconsistency in labels and measuring devices ... MD, assistant professor of pediatrics at NYU School of Medicine ...
... able to use medical means to restrict the growth of ... at home? A working group convened to discuss the ethical ... an article in the Hastings Center Report . Personal ... or speak -- accompany the article Growth attenuation is ...
... Nov. 30 (HealthDay News) -- Patients have better outcomes ... a new review. The researchers analyzed 298 studies ... led to improved outcomes in a number of important ... and lower cholesterol. Pharmacist participation in patient care ...
... -- Primary school children cannot accurately estimate the speed of ... a new study. "This is not a matter of ... visual detection mechanisms," John Wann, lead researcher and a professor ... of London, said in a university news release. ...
Cached Medicine News:Health News:Workers With Low Back Pain Benefit From Integrated Care 2Health News:CT best at uncovering drug mule payload 2Health News:Instructions on over-the-counter medications for children are found to be confusing 2Health News:Recommendations issued on controversial 'Ashley' procedure for disabled children 2Health News:Kids Can't Accurately Judge Speed of Approaching Cars: Study 2
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
Medicine Products: